Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT326 + BNT327 in advanced non-small cell lung cancer
2024-519344-32-00Phase 2Authorised
- Sponsor
- BioNTech SE
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of YL202 and pumitamig in non-small cell lung cancer (NSCLC) (5 arms), sponsored by BioNTech SE. Primary endpoints: Dose-limiting toxicities, Treatment-emergent and treatment-related adverse events and 2 more. Planned start Mar 2026; status: authorised.
02
Drugs
YL202pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-519344-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519344-32-00.